EQS-News: Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet
|
EQS-News: Epigenomics AG
/ Key word(s): Personnel
Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024. Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024. For the time being, Mr. Hummel's appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024. Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011. As a tax advisor and specialist consultant for international tax law, he is an expert in the field of corporate transactions, international tax law and group structures. Dr. Helge Lubenow, Chairwoman of the Supervisory Board: “We are very much looking forward to working with Mr. Hummel and his extensive expertise, which will enrich our Board.”
Contact: Investor Relations
Note on forward-looking statements This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
15.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Epigenomics AG |
| Bertha-Benz-Straße 5 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A37FT41 |
| WKN: | A37FT4 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1838167 |
| End of News | EQS News Service |
|
|
1838167 15.02.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 1,53 | 1,13 | 0,84 | 6,20 | 0,49 | 0,34 | 0,00 | |
| EBITDA1,2 | -12,78 | -14,16 | -11,09 | -1,94 | -11,30 | -2,91 | 0,00 | |
| EBITDA-Margin3 | -835,29 | -1.253,10 | -1.320,24 | -31,29 | -2.306,12 | -855,88 | 0,00 | |
| EBIT1,4 | -12,90 | -14,67 | -11,63 | -2,35 | -12,05 | -4,50 | 0,00 | |
| EBIT-Margin5 | -843,14 | -1.298,23 | -1.384,52 | -37,90 | -2.459,18 | -1.323,53 | 0,00 | |
| Net Profit (Loss)1 | -12,69 | -17,02 | -11,69 | -2,43 | -12,02 | -4,46 | 0,00 | |
| Net-Margin6 | -829,41 | -1.506,20 | -1.391,67 | -39,19 | -2.453,06 | -1.311,77 | 0,00 | |
| Cashflow1,7 | -10,35 | -13,51 | -9,57 | -4,15 | -12,02 | -5,71 | 0,00 | |
| Earnings per share8 | -75,20 | -73,00 | -40,40 | -4,40 | -14,80 | -5,15 | -3,00 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Epigenomics | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A37FT4 | DE000A37FT41 | AG | 0,97 Mio € | 19.07.2004 | 9F4MG9F8+6P | |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -0,99 | 0,00 | 0,00 | -0,02 | -0,12 | -0,17 | 2,87 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 29.05.2024 | 30.09.2024 | 14.03.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +10,41% | +5,23% | -40,32% | -40,80% | -99,92% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
